SS
Ultragenyx Pharmaceutical Pipeline
| Drug | Indication | Phase |
|---|---|---|
| DTX301 | Ornithine Transcarbamylase (OTC) Deficiency | Phase 3 |
| UX053 | Glycogen Storage Disease Type III (GSDIII) | Phase 3 |
| UX016 | GNE Myopathy | Phase 1/2 |
| DTX401 | Glycogen Storage Disease Type Ia (GSDIa) | Phase 3 |
| GTX-102 | Angelman Syndrome | Phase 1/2 |
| UX701 | Wilson Disease | Phase 1/2 |
| Crysvita (burosumab) | X-Linked Hypophosphatemia (XLH) | Approved |
| Dojolvi (triheptanoin) | Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) | Approved |
Leadership Team at Ultragenyx Pharmaceutical
ED
Emil D. Kakkis
Chief Executive Officer and President
EC
Eric Crombez
Chief Medical Officer
TH
Ted Huizenga
Chief Financial Officer
MR
Matthew R. Patterson
Chairman of the Board
KP
Karah Parschauer
Chief Legal Officer and Corporate Secretary
JM
John M. Higgins
Chief Business Officer